Test my supply
+6 more ↓
66%
Finnrick rating
#230 of 301 ranked vendors
73 of 97 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Uther's purity-focus record is product-specific, with PT-141 and Semaglutide reading cleaner while Survodutide and CJC-1295 carry the clearest weak signals. Recent testing shows recoveries in several lines, but identity failures, purity misses, volatile fills, and frequent batch-ID gaps keep the evidence dispersed despite broad volume.

methodology →
vendor intelligence report
Vendor Intelligence Report: Uther

We investigated who actually operates Uther — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

33 pages6 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.10
83%
8
2
Tirzepatide
$0.80
80%
16
3
Retatrutide
$2.00
77%
17
4
PT-141
-
75%
4
7
Mazdutide
-
72%
2
8
BPC-157
$1.00
67%
11
10
Tesamorelin
$1.35
58%
10
11
Cagrilintide
$3.00
56%
4
12
CJC-1295
$2.60
43%
6
14
TB-500
$2.50
39%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%26 Jan 2026: 57%26 Jan 2026: 57%10 Feb 2026: 59%10 Feb 2026: 60%10 Feb 2026: 61%10 Feb 2026: 61%18 Feb 2026: 60%20 Feb 2026: 61%26 Feb 2026: 61%1 Mar 2026: 61%2 Mar 2026: 61%2 Mar 2026: 61%4 Mar 2026: 61%4 Mar 2026: 61%4 Mar 2026: 61%6 Mar 2026: 61%6 Mar 2026: 61%6 Mar 2026: 62%6 Mar 2026: 62%6 Mar 2026: 62%6 Mar 2026: 62%7 Mar 2026: 63%7 Mar 2026: 63%13 Mar 2026: 63%20 Mar 2026: 64%25 Mar 2026: 64%23 Apr 2026: 65%28 Apr 2026: 65%28 Apr 2026: 65%28 Apr 2026: 65%28 Apr 2026: 66%28 Apr 2026: 65%8 May 2026: 65%1 Jun 2026: 65%8 Jun 2026: 66%8 Jun 2026: 66%8 Jun 2026: 66%1 Jul 2026: 66%20 Jul 2026: 66%20 Jul 2026: 66%10 Aug 2026: current 66%57%65%66%Jan 26Aug 26
Test my supply
Uther test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
20 Jul 2026Pass
GHK-Cu
lab nameView COA
20 Jul 2026Pass
Tirzepatide
lab nameView COA
1 Jul 2026Pass
Tesamorelin
lab nameView COA
8 Jun 2026Pass
Ipamorelin
lab nameView COA
8 Jun 2026Pass
Tesamorelin
lab nameView COA
8 Jun 2026Pass
Retatrutide
lab nameView COA
6 Jun 2026Incomplete
Retatrutide
lab nameView COA
6 Jun 2026Incomplete
Tesamorelin
lab nameView COA
6 Jun 2026Incomplete
Ipamorelin
lab nameView COA
1 Jun 2026Pass
Cagrilintide
lab nameView COA
1-10 of 100

About Uther test results from Finnrick

Uther is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 100 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Uther peptides in this dataset are BPC-157 (11 tests) and CJC-1295 (6 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 100 recent tests.

Corrections
No corrections.
Test my supply